News
NETRF 2025 BTSI Awardee Spotlight: Advancing GEP-NET Research with Suzann Duan, PhD
We’re proud to celebrate Dr. Suzann Duan, an Assistant Professor in the Department of Pharmaceutical Sciences at UC Irvine, as the recipient of the 2025 Basic/Translational
Expanding the Frontier of Neuroendocrine Tumor Imaging
By Anna Greene, PhD, NETRF Director of Research Dr. Benjamin Viglianti, recipient of a 2023 NETRF Investigator Award, is the senior author of a newly
Opening Doors for Innovation in Nuclear Medicine Research
NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with
Rethinking Time and Biology in SI-NETs: Two New Studies Signal a New Era for Patients
By Anna Greene, PhD, NETRF Director of Research What if small intestine neuroendocrine tumors (SI-NETs), often diagnosed in people over age 60, actually begin decades
Bridging the Nutritional Gap in Neuroendocrine Neoplasms: An ENETS Position Statement
By Anna Greene, PhD, NETRF Director of Research An important advancement in neuroendocrine neoplasm (NEN) patient care has been released: the Position Statement on Nutritional
CAR T-cell Clinical Trial Shows Promise, Advances to Next Dose Level
The world’s first clinical trial for CAR T-cell therapy in neuroendocrine tumors has advanced to a higher dose level, an indication of progress. Advancing to
When Watching Isn’t Enough: Somatostatin Analogs Show Promise in Small Pancreatic NETs
By Anna Greene, PhD, NETRF Director of Research For many patients newly diagnosed with small, nonfunctioning pancreatic neuroendocrine tumors (PanNETs), active surveillance (AS) with regular
Reimagining the Final Chapter: The Critical Role of Palliative Care in Neuroendocrine Tumors
By Anna Greene, PhD, NETRF Director of Research A recent study by Suriya Baskar, MD, and Udhayvir Singh Grewal, MD, published in the Journal of
Clinical Trial for NET Treatment Moves to Higher Dose Testing
Perspective Therapeutics has begun enrolling participants into the next phase of its clinical trial of a new targeted alpha radiation therapy for neuroendocrine tumors (NETs).
Living My Neuroendocrine Cancer Journey Out Loud
“Where do you see yourself in five years?” I’ve stopped answering that question. Five years ago I was 31. Five years ago I was planning my wedding. Five